A 1-year open-label safety extension study of pregabalin in patients with anxiety disorders

Trial Profile

A 1-year open-label safety extension study of pregabalin in patients with anxiety disorders

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Anxiety disorders
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top